Patents by Inventor Mari Ohtsuka

Mari Ohtsuka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6958353
    Abstract: The invention is directed to an imidazole derivative represented by formula (1): wherein each of R1 and R2 represents an aryl group, a heteroaryl group, etc.; each of A, X1, and X2 represents N or CH; each of Y and Z represents O, S, etc.; each of R3, R4, and R5 represents a hydrogen atom, an alkyl group, etc.; m is a number of 1 to 4; and n is a number of 0 to 4, or a salt thereof. The invention is also directed to a drug containing the derivative or the salt as an active ingredient. These compounds exert excellent effects of inhibiting production of NO and IL-6 and are useful for preventing or treating diseases induced by overproduction of NO and IL-6.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: October 25, 2005
    Assignee: Hisamitsu Medical Co., Ltd.
    Inventors: Fujiko Konno, Yoshihiro Nagao, Kazuo Isomae, Mari Ohtsuka, Yoshiyuki Takahashi, Fumio Ishii, Hiroyuki Hirota, Sunao Takeda, Noriyuki Kawamoto, Haruyoshi Honda, Susumu Sato
  • Publication number: 20030207896
    Abstract: The invention is directed to an imidazole derivative represented by formula (1): 1
    Type: Application
    Filed: November 5, 2002
    Publication date: November 6, 2003
    Inventors: Fujiko Konno, Yoshihiro Nagao, Kazuo Isomae, Mari Ohtsuka, Yoshiyuki Takahashi, Fumio Ishii, Hiroyuki Hirota, Sunao Takeda, Noriyuki Kawamoto, Haruyoshi Honda, Susumu Sato
  • Patent number: 5922767
    Abstract: Disclosed herein are substituted benzylurea derivatives represented by the following general formula (1): ##STR1## wherein R.sup.1 and R.sup.2 are independently H, a halogen atom, or an alkyl or alkoxyl group, R.sup.3 is a phenyl or heterocyclic group which may be substituted, n is an integer of 1-6, and R.sup.4 is a phenyl group which may be substituted, or salts thereof, and medicines comprising such a derivative as an active ingredient. The derivatives or salts thereof strongly inhibit only ACAT in macrophages and are hence useful as prophylactic and therapeutic agents for arteriosclerosis.
    Type: Grant
    Filed: October 7, 1997
    Date of Patent: July 13, 1999
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Yoshihiko Kanamaru, Hiroyuki Hirota, Akihiro Shibata, Teruo Komoto, Hiroyuki Naito, Koichi Tachibana, Mari Ohtsuka, Fumio Ishii, Susumu Sato
  • Patent number: 5902826
    Abstract: A diamine-platinum (IV) complex represented by the following formula (1): ##STR1## wherein R.sup.1 and R.sup.2 together represent R.sup.5 O--CH(CH.sub.2 NH.sub.2).sub.2 (R.sup.5 represents hydrogen, acetyl, trifluoroacetyl, benzoyl, cycloalkylcarbonyl or methanesulfonyl) or a C.sub.5-8 1,2-cycloalkanediamine; R.sup.3 and R.sup.4 each represents hydrogen or R.sup.6 CO-- (R.sup.6 represents alkyl, halogenoalkyl, cycloalkyl, aryl or aralkyl); and two X's together represent a malonic acid residue or glycolic acid residue which may have a substituent capable of coordinating to the platinum in formula (1) by an O,O-coordination or an N-acylamino acid residue coordinating to the platinum in formula (1) by an O,N-coordination; and a pharmaceutical composition comprising as an active ingredient the above-described diamine-platinum (IV) complex.
    Type: Grant
    Filed: December 23, 1997
    Date of Patent: May 11, 1999
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Kinichi Mogi, Hidehiko Koya, Mari Ohtsuka, Hiroyuki Mizuno, Susumu Sato
  • Patent number: 5866609
    Abstract: Disclosed herein are substituted vinylurea derivatives represented by the following general formula (1): ##STR1## wherein R.sup.1 and R.sup.3 are independently a phenyl group which may be substituted, R.sup.2 is a phenyl group which may be substituted, or a cycloalkyl group, and wave lines mean that the bonding state may be either E or Z, with the proviso that the cases where R.sup.1, R.sup.2 and R.sup.3 are unsubstituted phenyl groups, and where R.sup.1 and R.sup.2 are unsubstituted phenyl groups and R.sup.3 is a 4-ethoxyphenyl group are excluded, or salt thereof, and medicines comprising such a derivative as an active ingredient as well as a method of preventing and treating arteriosclerosis with such a medicine. The derivatives or salts thereof selectively and strongly inhibit ACAT in macrophages and are hence useful as prophylactic and therapeutic agents for arteriosclerosis.
    Type: Grant
    Filed: July 24, 1997
    Date of Patent: February 2, 1999
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Yoshihiko Kanamaru, Hiroyuki Hirota, Akihiro Shibata, Teruo Komoto, Hiroyuki Naito, Koichi Tachibana, Mari Ohtsuka, Fumio Ishii, Susumu Sato
  • Patent number: 5585511
    Abstract: A platinum complex represented by the following formula (1): ##STR1## wherein the all symbols are defined in the disclosure; and a malignant tumor treating drug which contains the complex as an active ingredient. The platinum complex is excellent in antitumor effects and safety and is highly soluble in water, and therefore it is useful as an agent for use in the treatment of various malignant tumors.
    Type: Grant
    Filed: December 26, 1995
    Date of Patent: December 17, 1996
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Koichi Yokoi, Kinichi Mogi, Hidehiko Kohya, Mari Ohtsuka, Hiroyuki Mizuno, Susumu Sato, Tadayuki Kuraishi
  • Patent number: 5532371
    Abstract: An arylamide derivative of formula (1), a salt thereof and a therapeutic agent for hyperlipemia which comprises the derivative or salt: ##STR1## wherein Ar represents a group ##STR2## a naphthyl group, a pyridinyl group, a furyl group, a thienyl group, a quinolyl group or an indolyl group; Y represents a group ##STR3## and Q represents --O-- or a single bond, Z represents an alkylene group, and R.sup.4 represents a hydroxyl group, an alkoxy group or a group --NH(CH.sub.2).sub.m COOH.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: July 2, 1996
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Teruo Komoto, Hiroyuki Hirota, Susumu Sato, Mari Ohtsuka, Hidehiko Koya, Hiroyuki Mizuno, Tadayuki Kuraishi
  • Patent number: 5498780
    Abstract: A diamine-platinum complex represented by the following formula (1): ##STR1## wherein the all definitions are defined in the disclosure, and a malignant tumor treating drug which contains the above complex as an active ingredient. The diamine-platinum complex has a high water solubility and an excellent antitumor effect.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: March 12, 1996
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Koichi Yokoi, Kinichi Mogi, Hidehiko Kohya, Mari Ohtsuka, Hiroyuki Mizuno, Susumu Sato, Tadayuki Kuraishi
  • Patent number: 5411972
    Abstract: An arylamide derivative of formula (1), a salt thereof and a therapeutic agent for hyperlipemia which comprises the derivative or salt: ##STR1## wherein Ar represents a group ##STR2## a naphthyl group, a pyridinyl group, a furyl group, a thienyl group, a quinolyl group or an indolyl group; Y represents a group ##STR3## and Q represents --O-- or a single bond, Z represents an alkylene group, and R.sup.4 represents a hydroxyl group, an alkoxy group or a group --NH(CH.sub.2).sub.m COOH, useful for the treatment and prevention of hyperlipemia due to their excellent cholesterol reducing action, triglyceride reducing action and high safety.
    Type: Grant
    Filed: November 29, 1993
    Date of Patent: May 2, 1995
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Teruo Komoto, Hiroyuki Hirota, Susumu Sato, Mari Ohtsuka, Hidehiko Koya, Hiroyuki Mizuno, Tadayuki Kuraishi
  • Patent number: 4942172
    Abstract: A method of curing or alleviating hepatic disease comprising administrating to the patient 1,3-dithiole-2-thione or 1,3-dithiolane-2-thione is disclosed. Adminstration of the compound can be made in various dosing forms, including tablets, granules, powders, capsules, suspensions, injections, and suppositories. Normal dosing amount can be determined from the range of 0.01 to 50 mg/kg/day for oral administration, and 0.002 to 10 mg/kg/day for injection or other forms of administration.
    Type: Grant
    Filed: May 20, 1988
    Date of Patent: July 17, 1990
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Hitoshi Nakazawa, Mari Ohtsuka, Hideaki Matsuda, Tatsuhiko Katori, Kazuhiko Irinoda